Robocath

WATCH CPS 31

Endovascular surgical robots for interventional cardiology, neurointerventions, and electrophysiology procedures

ACQUIRED ↓ JSON ↓ MD
Researched 2026-04-15 ● Current
Robocath — robotics.press intelligence card

Robocath is a clinically grounded but commercially nascent PCI robotics company with only ~€727k in 2022 revenue despite $57.9M in funding and 15+ years of operation. The definitive acquisition by Stereotaxis (April 2026) is a strategically sound exit that could unlock commercial scale, but the company has yet to demonstrate repeatable revenue traction, and the endovascular robotics market remains early-stage with uncertain TAM and intense competitive dynamics from incumbents like Siemens/Corindus.

Moat NARROW

- Claimed unique European commercial availability for robotic PCI (R-One+), though this is a temporary positioning advantage subject to competitor launches - Open architecture compatibility with leading cath lab devices reduces hospital switching friction - CE marking and China NMPA regulatory approvals create modest barriers to entry in approved geographies - Proprietary bionic technology and precision actuation in second-generation platform (pending clinical validation)

Management ADEQUATE

Founder Philippe Bencteux, MD brings deep clinical insight and 15+ years of tenure, which ensures strong product-clinical fit. However, the very low commercial traction (~€727k revenue after $57.9M raised) raises questions about commercial execution capability. The addition of independent strategic committee members in 2021 and active Medical Advisory Board engagement (Haude, Fajadet) are positive governance signals, but the team of ~62 employees appears under-resourced for global commercialization without the Stereotaxis acquisition.

Financials OPAQUE
Bull Case

Stereotaxis acquisition (April 2026) provides commercial infrastructure, global distribution, and complementary magnetic navigation technology to accelerate go-to-market across endovascular procedures

R-One+ claimed to be the only commercially available robotic PCI solution in Europe per Stereotaxis CEO, suggesting a temporary but meaningful availability niche

China NMPA approval obtained in 2024 for R-One platform, opening access to one of the world's fastest-growing PCI markets

Second-generation robot entered FIH clinical study (Jan 2026) targeting complex CAD cases with 20 patients, expanding the robotically addressable procedure mix

Open architecture design compatible with leading cath lab devices reduces switching costs for hospitals and differentiates from closed-ecosystem competitors

Strong KOL engagement via Medical Advisory Board (Haude, Fajadet) and multicenter clinical programs (R-Evolution, CHANGE registry) support credibility and adoption pathways

Bear Case

Revenue of only ~€727k in FY2022 after $57.9M in funding and 13 years of operation signals severe commercialization challenges; no updated revenue data available for 2023-2025

Endovascular robotics TAM estimates vary wildly ($61M to $1.8B depending on source), creating significant uncertainty about the addressable opportunity

Competitive intensity from Siemens Healthineers (Corindus/CorPath), Stereotaxis itself, and venture-backed innovators (Remedy Robotics, XCath, Nanoflex) threatens sustained differentiation

Integration risk with Stereotaxis is material: aligning product roadmaps, field organizations, manufacturing scale-up, and disposable supply chains for a 62-person team is non-trivial

No FDA approval or U.S. market access pathway disclosed, limiting near-term revenue potential in the world's largest medtech market

Hospital capital expenditure headwinds and competing priorities (imaging, hybrid ORs, structural heart) can delay adoption of nascent robotic platforms with unproven ROI

Key Risks

Post-acquisition integration execution with Stereotaxis: misalignment on roadmap, culture, or go-to-market could destroy value

No disclosed revenue data since FY2022; installed base size and disposable utilization rates remain opaque

Lack of FDA approval limits access to the largest global medtech market; no U.S. regulatory pathway has been disclosed

Competitive response from Siemens/Corindus and emerging players could erode any temporary European availability advantage

Scaling sterile disposable manufacturing while maintaining quality and margins is a known challenge for small robotic platform companies

Clinical evidence remains limited to small cohorts and company-stated outcomes; no large randomized trials or health-economic data published

Catalysts

Completion and results of the 20-patient FIH study for the second-generation robot (expected 2026-2027)

Closing of Stereotaxis acquisition and first evidence of commercial synergies (bundled sales, expanded geography)

Post-NMPA commercial traction in China: first institutional placements and procedure volumes

Potential U.S. FDA regulatory pathway announcement under Stereotaxis umbrella

Publication of peer-reviewed multicenter outcomes data from R-Evolution or CHANGE registry

Irreplaceability 3
Market Weight
Tech Differentiation
Operational Deployment
Strategic Momentum
Ecosystem Influence
Coverage Necessity
Fin. Valuation
Fin. Revenue
TypeQuick Research
Published2026-04-15
Length2,073 words · 9 min read
Sources11 sources cited
↓ Download Report ↓ JSON

Generated by automated research. Cross-reference with primary sources before investment decisions.

R-One Fixed · FIELDED
└─ First-generation robotic platform for minimally invasive percutaneous coronary interventions (PCI) with remote manipulation of guidewires and catheters from a protected workstation. Comprises a radiation protection screen and robotic module with articulated support arm for precision catheter/guidewire control. China NMPA approval received in 2024 per trade press indexed by Tracxn. Early clinical use included first robotic coronary angioplasties and carotid stenting in France (2021) and second coronary angioplasty in China (2021). Subject of ongoing CHANGE registry with at least 100 patients at one institution and R-Evolution multicenter European study.
R-One+ Fixed · FIELDED · Launched 2023
└─ Next-generation evolution of the R-One platform for percutaneous coronary interventions, launched mid-2023. Described as the only commercially available robotic solution for PCI in Europe at the time of the Stereotaxis acquisition announcement. Described by Stereotaxis CEO at time of acquisition announcement (April 15, 2026) as the only commercially available robotic solution for PCI in Europe. Trade press coverage of mid-2023 launch indexed by Tracxn via Medical Product Outsourcing and PharmaTimes.
Second-Generation Robot Fixed · PROTOTYPE · Launched 2026
└─ Next-generation robotic platform currently in first-in-human (FIH) clinical trials as of January 2026. Features unique bionic technology, precision actuation, and open architecture compatible with leading cath lab devices. Designed for complex coronary artery disease cases with potential for remote interventions/telerobotics. FIH study launched January 27, 2026 at Centre Cardiologique du Nord, Saint-Denis, France. Designed to address complex PCI cases beyond the scope of first-generation platforms. Open architecture is intended to be compatible with leading cath lab devices from multiple manufacturers. Telerobotics capability targets remote vascular interventions and emergencies as a longer-term application vector. Builds on lessons from R-One and R-One+ platforms.
Philippe Bencteux Founder and President
Mohammed Nejjari Principal Investigator, FIH Clinical Study (Second-Generation Robot)
Franck Digne Co-Investigator, FIH Clinical Study (Second-Generation Robot)
Michael Haude Medical Advisory Board Member
Jean Fajadet Medical Advisory Board Member

News & Analysis

1
Robocath: Company ProfileAnalysis
2026-04-26